Telix Pharmaceuticals Limited
TLX
Classificação em ações
#4433
Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical... Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical company dedicated to pioneering molecularly targeted radiation (MTR) products. These innovations are developed for the diagnosis and treatment of various cancers and rare conditions, with its global presence encompassing Australia, Belgium, Japan, Switzerland, and the United States. The company's robust pipeline includes several leading candidates. TLX591-CDx is engineered for the diagnosis and treatment of metastatic castrate-resistant prostate cancer, while TLX66-CDx is designed for bone marrow conditioning and rare diseases. In advanced clinical development, TLX250-CDx is in Phase III trials for renal (kidney) cancer diagnosis and treatment, alongside TLX250 in Phase II for the same indication. TLX591 is also undergoing Phase III trials for metastatic castrate-resistant prostate cancer. For glioblastoma (brain cancer), TLX101 and TLX101-CDx are currently in Phase I/II studies, and TLX66 is in Phase I/IIa trials for bone marrow conditioning and rare diseases. Beyond these flagship programs, Telix is actively developing TLX592, a targeted alpha therapy candidate for prostate cancer. Its portfolio also features TLX591-Sx, a versatile PET tracer capable of both PET and fluorescent (optical) imaging, and TLX599-CDx, an investigational prostate cancer imaging agent utilizing single-photon emission computed tomography (SPECT). Strategic collaborations are integral to Telix's operations. This includes a significant license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for MTR product development, a scientific and clinical research alliance with Mauna Kea Technologies, and a strategic collaboration agreement with Lightpoint Medical, Ltd. Founded in 2015, the company's headquarters are located in North Melbourne, Australia.
Preço da ação
$10.35
Valor de mercado
$3.52B
Variação (1 dia)
0.03%
Variação (1 ano)
-5.93%
País
AU
Negociar Telix Pharmaceuticals Limited (TLX)
Categoria
Healthcare
Rácio P/E de Telix Pharmaceuticals Limited (TLX)
Rácio P/E em October 2026 TTM: 109.12
De acordo com os últimos relatórios financeiros e o preço das ações da Telix Pharmaceuticals Limited, o rácio P/E atual (TTM) é 109.12. No final de 2023, a empresa tinha um P/E de 617.41.
Histórico do rácio P/E da Telix Pharmaceuticals Limited de 2000 a 2026
Rácio P/E no final de cada ano
| Ano | Índice P/E | Alterar |
|---|---|---|
| 2026 (TTM) | 109.12 | -33.18% |
| 2024 | 163.29 | -73.55% |
| 2023 | 617.41 | -2,945.40% |
| 2022 | -21.70 | -20.12% |
| 2021 | -27.17 | 25.39% |
| 2020 | -21.67 | 66.86% |
| 2019 | -12.98 | 36.68% |
| 2018 | -9.50 | -27.18% |
| 2017 | -13.05 | -99.42% |
| 2016 | -2.24K | 360.80% |
| 2015 | -486.09 | 711.45% |
| 2000 | -59.90 | 0.00% |
Rácio P/E para empresas semelhantes ou concorrentes
| Empresa | Rácio P/E | Diferença do rácio P/E | País |
|---|---|---|---|
| 28.78 | -73.62% |
US
|
|
| -28.36 | -125.99% |
US
|
|
| -24.57 | -122.51% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -72.20% |
NL
|
Como interpretar um P/E Ratio?
O rácio Preço/Lucro (P/E) mede a relação entre o preço da ação de uma empresa e o lucro por ação.
Um P/E baixo mas positivo representa uma empresa com altos lucros face à sua valorização atual e pode estar subvalorizada. Um P/E negativo elevado (perto de 0) representa perdas significativas.
Empresas com P/E acima de 30 ou negativo são geralmente vistas como "ações de crescimento", significando que os investidores esperam crescimento ou rentabilidade futura.
Empresas com P/E positivo inferior a 10 são geralmente consideradas "ações de valor", ou seja, já são muito lucrativas mas com pouco potencial de crescimento.